Function of fibroblast growth factors and vascular endothelial growth factors and their receptors in angiogenesis

Critical Reviews in Oncology/Hematology

Volumn 34, Issue 3, 2000, Pages 185-194

  Gerwins, Pär ^a   Sköldenberg, Erik ^b,c   Claesson Welsh, Lena ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Angiogenesis; FGF; Oncology; Signal transduction; VEGF

Indexed keywords

FIBROBLAST GROWTH FACTOR; PROTEIN TYROSINE KINASE; VASCULOTROPIN;

ANGIOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL STIMULATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; HUMAN; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ENDOTHELIAL GROWTH FACTORS; FIBROBLAST GROWTH FACTORS; GENE THERAPY; HUMANS; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034127430     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(00)00062-7     Document Type: Review

References (94)

1. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995;11:73-91.
2. Flamme I, Frolich T, Risau W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J Cell Physiol 1997;173:206-10.
3. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671-4.
4. Ferrara N. Vascular endothelial growth factor: molecular and biological aspects. Curr Top Microbiol Immunol 1999;237:1-30.
5. Galzie Z, Kinsella AR, Smith JA. Fibroblast growth factors and their receptors. Biochem Cell Biol 1997;75:669-85.
6. Rabbani SA. Metalloproteases and urokinase in angiogenesis and tumor progression. In Vivo 1998;12:135-42.
7. Hirschi KK, D'Amore PA. Control of angiogenesis by the pericyte: molecular mechanisms and significance. Exs 1997;79:419-28.
8. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998;4:655-7.
9. Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999;237:97-132.
10. Kavanaugh WM, Williams LT. Signal transduction. In: Heldin CH, Purton M, editors. Signalling Through Receptor Tyrosine Kinases. London: Chapman and Hall, 1996:3-18.
11. Pawson T. Signal transduction in the control of cell growth and development. Trends Genet 1991;7:343-5.
12. Beck L Jr, D'Amore PA. Vascular development: cellular and molecular regulation. FASEB J 1997;11:365-73.
13. Bussolino F, Mantovani A, Persico G. Molecular mechanisms of blood vessel formation. Trends Biochem Sci 1997;22:251-6.
14. Pepper MS, Ferrara N, Orci L, et al. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun 1992;189:824-31.
15. Goto F, Goto K, Weindel K, et al. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels [see comments]. Lab Invest 1993;69:508-17.
16. Asahara T, Bauters C, Zheng LP, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 1995;92:II365-71.
17. Ogawa S, Oku A, Sawano A, et al. A novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J Biol Chem 1998;273:31273-82.
18. Eriksson U, Alitalo K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 1999;237:41-57.
19. Persico MG, Vincenti V, DiPalma T. Structure, expression and receptor-binding properties of placenta growth factor (PlGF). Curr Top Microbiol Immunol 1999;237:31-40.
20. Meyer M, Clauss M, Lepple-Wienhues A, et al. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases. EMBO J 1999;18:363-74.
21. Cao Y, Linden P, Shima D, et al. In vivo angiogenic activity and hypoxia induction of heterodimers of placenta growth factor/ vascular endothelial growth factor. J Clin Invest 1996;98:2507-11.
22. DiSalvo J, Bayne ML, Conn G, et al. Purification and characterization of a naturally occurring vascular endothelial growth factor placenta growth factor heterodimer. J Biol Chem 1995;270:7717-23.
23. Olofsson B, Pajusola K, Kaipainen A, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA 1996;93:2576-81.
24. Houck KA, Ferrara N, Winer J, et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806-14.
25. Houck KA, Leung DW, Rowland AM, et al. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J Biol Chem 1992;267:26031-7.
26. Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266:11947-54.
27. Dumont DJ, Fong GH, Puri MC, et al. Vascularization of the mouse embryo: a study of flk-1, tek, tie, and vascular endothelial growth factor expression during development. Dev Dyn 1995;203:80-92.
28. Berse B, Brown LF, Van de Water L, et al. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992;3:211-20.
29. Breier G, Damert A, Plate KH, et al. Angiogenesis in embryos and ischemic diseases. Thromb Haemost 1997;78:678-83.
30. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31.
31. Damert A, Machein M, Breier G, et al. Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res 1997;57:3860-4.
32. Shibuya M, Ito N, Claesson-Welsh L. Structure and function of vascular endothelial growth factor receptor-1 and -2. Curr Top Microbiol Immunol 1999;237:59-83.
33. Korpelainen EI, Alitalo K Signaling angiogenesis and lymphangiogenesis. Curr Opin Cell Biol 1998;10:159-64.
34. Heldin CH. Dimerization of cell surface receptors in signal transduction. Cell 1995;80:213-23.
35. Pawson T, Scott JD. Signaling through scaffold, anchoring, and adaptor proteins. Science 1997;278:2075-80.
36. Pawson T. Protein modules and signalling networks. Nature 1995;373:573-80.
37. Cunningham SA, Arrate MP, Brock TA, et al. Interactions of FLT-1 and KDR with phospholipase C γ: identification of the phosphotyrosine binding sites. Biochem Biophys Res Commun 1997;240:635-9.
38. Sawano A, Takahashi T, Yamaguchi S, et al. The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLC γ. Biochem Biophys Res Commun 1997;238:487-91.
39. Dougher-Vermazen M, Hulmes JD, Bohlen P, et al. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem Biophys Res Commun 1994;205:728-38.
40. Ito N, Wernstedt C, Engstrom U, et al. Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules. J Biol Chem 1998;273:23410-8.
41. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999;18:2221-30.
42. Schonwasser DC, Marais RM, Marshall CJ, et al. Activation of the mitogen-activated protein kinase/extracellular signal- regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 1998;18:790-8.
43. Rousseau S, Houle F, Landry J, et al. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene 1997;15:2169-77.
44. Kroll J, Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J Biol Chem 1997;272:32521-7.
45. Seetharam L, Gotoh N, Maru Y, et al. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995;10:135-47.
46. Soker S, Takashima S, Miao HQ, et al. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998;92:735-45.
47. Clauss M, Weich H, Breier G, et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 1996;271:17629-34.
48. Kremer C, Breier G, Risau W, et al. Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res 1997;57:3852-9.
49. Nishimura T, Utsunomiya Y, Hoshikawa M, et al. Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta 1999;1444:148-51.
50. Spivak-Kroizman T, Lemmon MA, Dikic I, et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994;79:1015-24.
51. Basilico C, Moscatelli D. The FGF family of growth factors and oncogenes. Adv Cancer Res 1992;59:115-65.
52. La Vallee TM, Tarantini F, Gamble S, et al. Synaptotagmin-1 is required for fibroblast growth factor-1 release. J Biol Chem 1998;273:22217-23.
53. Tarantini F, La Vallee T, Jackson A, et al. The extravesicular domain of synaptotagmin-1 is released with the latent fibroblast growth factor-1 homodimer in response to heat shock. J Biol Chem 1998;273:22209-16.
54. Florkiewicz RZ, Majack RA, Buechler RD, et al. Quantitative export of FGF-2 occurs through an alternative, energy-dependent, non-ER/Golgi pathway. J Cell Physiol 1995;162:388-99.
55. Florkiewicz RZ, Anchin J, Baird A. The inhibition of fibroblast growth factor-2 export by cardenolides implies a novel function for the catalytic subunit of Na+, K+ -ATPase. J Biol Chem 1998;273:544-51.
56. Friesel RE, Maciag T. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J 1995;9:919-25.
57. Malek AM, Connors S, Robertson RL, et al. Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in moyamoya and central nervous system disorders. Pediatr Neurosurg 1997;27:182-9.
58. Jain RK, Schlenger K, Hockel M, et al. Quantitative angiogenesis assays: progress and problems. Nat Med 1997;3:1203-8.
59. Flamme I, Risau W. Induction of vasculogenesis and hematopoiesis in vitro. Development 1992;116:435-9.
60. Partanen J, Vainikka S, Korhonen J, et al. Diverse receptors for fibroblast growth factors. Prog Growth Factor Res 1992;4:69-83.
61. Peters KG, Werner S, Chen G, et al. Two FGF receptor genes are differentially expressed in epithelial and mesenchymal tissues during limb formation and organogenesis in the mouse. Development 1992;114:233-43.
62. Kanda S, Landgren E, Ljungstrom M, et al. Fibroblast growth factor receptor 1-induced differentiation of endothelial cell line established from tsA58 large T transgenic mice. Cell Growth Differ 1996;7:383-95.
63. Bastaki M, Nelli EE, Dell'Era P, et al. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. Arterioscler Thromb Vasc Biol 1997;17:454-64.
64. Kan M, Wang F, Xu J, et al. An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993;259:1918-21.
65. Guimond S, Maccarana M, Olwin BB, et al. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 1993;268:23906-14.
66. Mohammadi M, Dikic I, Sorokin A, et al. Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 1996;16:977-89.
67. Klint P, Claesson-Welsh L. Signal transduction by fibroblast growth factor receptors. Front Biosci 1999;4:D165-77.
68. Klint P, Kanda S, Kloog Y, et al. Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation. Oncogene 1999;18:3354-64.
69. Carmeliet P, Ferreira V, Breier G, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996;380:435-9.
70. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439-42.
71. Carmeliet P, Ng YS, Nuyens D, et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 [see comments]. Nat Med 1999;5:495-502.
72. Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995;376:62-6.
73. Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995;376:66-70.
74. Hiratsuka S, Minowa O, Kuno J, et al. Fit-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998;95:9349-54.
75. Dumont DJ, Jussila L, Taipale J, et al. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 1998;282:946-9.
76. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice [published erratum appears in Science 1997 July 25;277(5325):463]. Science 1997;276:1423-5.
77. Deng CX, Wynshaw-Boris A, Shen MM, et al. Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes Dev 1994;8:3045-57.
78. Yamaguchi TP, Harpal K, Henkemeyer M, et al. Fgfr-1 is required for embryonic growth and mesodermal patterning during mouse gastrulation. Genes Dev 1994;8:3032-44.
79. Dono R, Texido G, Dussel R, et al. Impaired cerebral cortex development and blood pressure regulation in FGF-2-deficient mice. EMBO J 1998;17:4213-25.
80. Henkemeyer M, Rossi DJ, Holmyard DP, et al. Vascular system defects and neuronal apoptosis in mice lacking ras GT-Pase-activating protein. Nature 1995;377:695-701.
81. Wojnowski L, Zimmer AM, Beck TW, et al. Endothelial apoptosis in Braf-deficient mice. Nat Genet 1997;16:293-7.
82. Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367:576-9.
83. Kendall RL, Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 1993;90:10705-9.
84. Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92:10457-61.
85. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4.
86. Mohammadi M, Froum S, Hamby JM, et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998;17:5896-904.
87. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
88. Partanen J, Dumont DJ. Functions of Tiel and Tie2 receptor tyrosine kinases in vascular development. Curr Top Microbiol Immunol 1999;237:159-72.
89. Davis S, Yancopoulos GD. The angiopoietins: Yin and Yang in angiogenesis. Curr Top Microbiol Immunol 1999;237:173-85.
90. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
91. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-85.
92. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
93. Cao Y. Endogenous angiogenesis inhibitors: angiostatin, endostatin, and other proteolytic fragments. Prog Mol Subcell Biol 1998;20:161-76.
94. Christofferson RH, Nilsson BO. Scanning electron microscopy of vascular casts: methods and applications. In: Motta PM, Murakami T, Fujita H, editors. Microvascular Corrosion Casting in Angiogenesis Research. Boston: Kluwer Academic Publishers, 1992:22-37.